A Phase 1/2 interventional study of Fluoxetine and Sertraline in Depression and Sequestra, sponsored by First Affiliated Hospital of Chongqing Medical University. Recruiting at 1 site in China. Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by First Affiliated Hospital of Chongqing Medical University · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing fluoxetine in Depression — 9 open to participants now, 10 under way, 1 of them phase 3. Fluoxetine · Depression.
Among the 43 studies testing fluoxetine in Depression, this one is the 5th largest by planned enrollment of the 42 interventional ones that give a count, is the only one that started in 2023, is one of 4 in phase 1/2, and was the 34th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →9 of the 43 studies testing fluoxetine in Depression are open now, in 7 countries. Recruiting first, the newest first:
University of Oxford · Sites in United Kingdom
Ages 18–24 · Healthy volunteers
University of Bern · Sites in Zimbabwe
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Poznan University of Medical Sciences · Sites in Poland
Ages 12+
Federal University of Latin American Integration · Sites in Brazil
Ages 25–65 · Healthy volunteers
By country, each count listing its studies:
Fluoxetine: first FDA approval 1987 (SARAFEM). What it is approved for, and how studies give it, is on its page →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 13 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 9 · Phase 4 9
First in 1995; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 520 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 97 across the 42 interventional studies. Of the 30 that completed or were terminated, 13 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 43 have an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital of Chongqing Medical University is the lead sponsor of 97 studies on the registry; 43 are open to participants now.
12 studies in Depression by First Affiliated Hospital of Chongqing Medical University: 7 open now, 7 under way, none of them phase 3. Of 3 finished, 0 (0%) have results posted.
Among the 12 studies in Depression by First Affiliated Hospital of Chongqing Medical University, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is the only one in phase 1/2, and was the 3rd registered.
First Affiliated Hospital of Chongqing Medical University’s Depression studies by the year they started, since 2015.
6 of the studies testing fluoxetine in Depression that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424781University of OxfordFluoxetine on Emotional Experience (FLEX) Study | 2026-12-31 |
| NCT05814640First Affiliated Hospital of Chongqing Medical UniversitySequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) | 2026-12-31 |
| NCT05976347Wake Forest University Health SciencesIdentifying and Treating Depression in the Orthopaedic Trauma Population | 2027-05 |
| NCT07456501University of OxfordFluoxetine and Understanding Social Experiences | 2027-07-20 |
| NCT07110831University of IbadanDisposition Kinetics of Dolutegravir Among People Living With HIV With Major Depression in Nigeria | 2027-09-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 43 studies testing fluoxetine in Depression, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among First Affiliated Hospital of Chongqing Medical University’s 12 in Depression:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This project aims to investigate the effectiveness of existing common antidepressants and to provide new evidence for depressed children and adolescents who are not responding to their first treatment.
This is an open-label Sequential Multiple Assignment Randomized Trial (SMART) of 16 weeks duration with two levels, each stage 8 weeks. In phase 1, adolescents with MDD will be selected into fluoxetine or fluoxetine combination CBT therapy groups and the choice of treatment will be at the discretion of the patient. Subjects who fail to respond will enter phase 2 randomization, where patients will be randomly assigned to oral sertraline, votioxetine, duloxetine or adding one of aripiprazole, lithium carbonate, and olanzapine to fluoxetine. The primary outcome of the treatment phase is the treatment remission rate and response rate. Secondary outcomes included: symptom scale; Quality of life; Sleep therapy; Symptoms of anxiety; Rumination and safety assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dosage form: po Dosage: 10-60mg Frequency: qn Course of treatment: 8 weeks. At week 8, patients will be evaluated as "in " or "not in remission." "Patients who are not in remission" will be randomized to phase II treatment based on the patient's wishes.
Drug: Fluoxetine
GCBT was administered in addition to fluoxetine and consisted of 11 sessions for 8 weeks. It lasts 90 to 120 minutes, once or twice a week. At week 8, patients will be evaluated as "in remission" or "not in remission." "Patients who are not in remission" will be randomized to phase II treatment based on the patient's wishes.
Behavioral: GCBT
dosage form: po dosage:25-200mg frequency:qn duration: At Week 8, patients assessed as 'non-remission' will be given Sertraline as a switching treatment to fluoxetine.
Drug: Sertraline
dosage form: po dosage: 10-20mg frequency:qn duration: At Week 8, patients assessed as 'non-remission' will be given votioxetine as a switching treatment to fluoxetine.
Drug: Vortioxetine
dosage form: po dosage: 60-120mg frequency: qn duration: At Week 8, patients assessed as 'non-remission' will be given duloxetine as an add-on treatment to fluoxetine.
Drug: Duloxetine
dosage form: po dosage: 2.5-15mg frequency:qn duration: At Week 8, patients assessed as 'non-remission' will be given aripiprazole as an add-on treatment to fluoxetine.
Drug: Aripiprazole
dosage form: po dosage: 125-500mg frequency: qn duration: At Week 8, patients assessed as 'non-response' will be given lithium carbonate as an add-on treatment to fluoxetine.
Drug: Lithium Carbonate
dosage form:po dosage: 1.25-10mg frequency:qn duration: At Week 8, patients assessed as 'non-rremission' will be given olanzapine as an add-on treatment to fluoxetine.
Drug: Olanzapine
Commonly used oral antidepressant.
Commonly used oral antidepressant.
Commonly used oral antidepressant.
Commonly used oral antidepressant.
Commonly used oral augmentation therapy for antidepressants
Commonly used oral augmentation therapy for antidepressants.
Commonly used oral augmentation therapy for antidepressants.
Commonly used intervention therapy of psychotherapy.
Change in CDRS-R (Children's Depression Rating Scale) scores from baseline
Clinical response (≥ 50% reduction in CDRS-R scores from baseline)
Time frame: Baseline of treatment period, 2 weeks, 1 month, 2 months, 3 months,4months; The follow-up period was 1 month, 3 months, 6 months and 12 months
Change in BDI-II (Baker Depression Scale) scores from baseline
Change in BDI-II (Baker Depression Scale) scores from baseline
Time frame: Baseline of treatment period, 1 month, 2 months, 3 months,4 months; The follow-up period was 1 month, 3 months, 6 months and 12 months
Change in SCARED (The Screen for Child Anxiety-Related Emotional Disorders) scores from baseline
Improvement in anxiety (SCARED minus the scores)
Time frame: Baseline of treatment period, 1 month, 2 months, 3 months,4 months; The follow-up period was 1 month, 3 months, 6 months and 12 months
Change in suicide risk from baseline on the C-SSRS (Columbia Suicide Severity Rating Scale)
The severity of the suicide risk
Time frame: Baseline of treatment period, 1 month, 2 months, 3 months,4 months; The follow-up period was 1 month, 3 months, 6 months and 12 months
Change in PSQI (Pittsburgh Sleep Quality Index) scores from baseline
Improvement in sleep status (PSQI minus the scores)
Time frame: Baseline of treatment period, 2 month, 4 months; The follow-up period was 1 month, 3 months, 6 months and 12 months
Change in PedsQL4.0 (The Pediatric Quality of Life Inventory) scores from baseline
Improvement of children's quality of life(PedsQL4.0 minus the scores)
Time frame: Baseline of treatment period, 2 month, 4 months; The follow-up period was 1 month, 3 months, 6 months and 12 months
Change in CGI-S (Clinical Global Impressions-Severity Scales) scores from baseline
Improvement in overall clinical impression severity( 7-point scale, with 1 being normal and 7 being among the most severely damaged)
Time frame: Baseline of treatment period, 1 month, 2 months, 3 months,4 months.
Change in CGI-I (Clinical Global Impressions-Improvement Scales) scores from baseline
Improvement of clinical general Impression scale( 7-point scale,7 denoting a very significant deterioration)
Time frame: The treatment period was 1 month, 2 months, 3 months,4 months.
Change in RSS (Ruminative Responses Scale)
The level of improvement in negative thinking(he higher the total score, the more reflective thinking The more severe it is)
Time frame: The treatment period was 1 month, 2 months.
Change in HCL-32(Hypomania Symptom Checklist-32)
Assess the patient's hypomanic state
Time frame: Baseline of treatment period, 1 month, 2 months, 3 months,4 months; The follow-up period was 1 month, 3 months, 6 months and 12 months
Started Feb 2023 (actual). Primary completion is estimated for Dec 2026, 46 months after the start.
Of 42 phase 1/2 interventional studies under Depression, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 46 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluoxetine · Sertraline · Vortioxetine · Duloxetine · Aripiprazole · Lithium Carbonate · Olanzapine
First Affiliated Hospital of Chongqing Medical University